Eczema often leads to absenteeism. More than half of people with eczema miss at least one day of work or school every year. For 26%, this can amount to a week, and 13% miss eleven days or more. People with severe symptoms or suboptimal treatment are particularly at risk of long-term absenteeism.
Current treatments can be inconvenient, cause side effects, or be prohibitively expensive. In contrast, blue light therapy offers a drug-free, UV-free, clinically validated solution that can be used at home. The patented Phlecs full-body blue light home device is expected to launch in the U.S. in 2027 and in Europe in 2028, offering a new standard of care for eczema patients worldwide. Dermatology clinics across Europe already have access to the full-body
